Home › Gilead paying up to $1.2B for Nimbus unit, drug candidate
 

Keywords :   


Gilead paying up to $1.2B for Nimbus unit, drug candidate

2016-04-04 22:15:41| Biotech - Topix.net

Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes life-threatening fat buildup in the liver. Gilead, based in Foster City, California, will pay $400 million for Nimbus Apollo Inc. Parent company Nimbus Therapeutics, based in Cambridge, Massachusetts, could receive another $800 million if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.

Tags: unit drug candidate paying

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Public Advisory Number 2
02.11Subtropical Storm Patty Forecast Advisory Number 2
02.11Subtropical Storm Patty Update Statement
More »